Monopar Therapeutics Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

2. Significant Accounting Policies (Tables)

2. Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2018

Assets and liabilities measured at fair value on a recurring basis

December 31, 2018		Level 1		Level 2		Total
	Assets
	Cash equivalents(1)	$	6,788,333	$	—	$	6,788,333
	Total	$	6,788,333	$	—	$	6,788,333

(1)

Cash equivalents represent the fair value of the Company’s investments in a money market account at December 31, 2018.

December 31, 2017		Level 1		Level 2		Total
	Assets
	Cash equivalents(1)	$	8,872,982	$	—	$	8,872,982
	Restricted cash(2)		31		800,000		800,031
	Total	$	8,873,013	$	800,000	$	9,673,013

(1) Cash equivalents represent the fair value of the Company’s investments in two money market accounts at December 31, 2017.

(2)	Restricted cash represents the fair value of the Company’s investments in an $800,000 certificate of deposit and $31 in a money market account at December 31, 2017.

- Definition

Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.

+ References + Details